JO3370B1 - طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 - Google Patents

طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Info

Publication number
JO3370B1
JO3370B1 JOP/2012/0332A JOP20120332A JO3370B1 JO 3370 B1 JO3370 B1 JO 3370B1 JO P20120332 A JOP20120332 A JO P20120332A JO 3370 B1 JO3370 B1 JO 3370B1
Authority
JO
Jordan
Prior art keywords
antagonist
methods
tumor growth
antagonizing
receptor
Prior art date
Application number
JOP/2012/0332A
Other languages
English (en)
Inventor
Zhang Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3370B1 publication Critical patent/JO3370B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي توفير طرق لتثبيط أو توهين نمو الورم في مريض بواسطة إعطاء IL-6 الى مريض. في نماذج محددة ، يتم استخدام طرق الاختراع لتثبيط نمو الورم المقاوم لمضاد VEGF في مريض. يمكن أن يكون مضاد IL-6، على سبيل المثال، عبارة عن جسم مضاد يرتبط نوعيا بـ IL-6R. يمكن إعطاء مضاد IL-6 بالاشتراك مع مضاد VEGF، و/أو مضاد EGFR، و/أو مضاد ErbB3.
JOP/2012/0332A 2011-11-10 2012-11-04 طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 JO3370B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US201261613538P 2012-03-21 2012-03-21

Publications (1)

Publication Number Publication Date
JO3370B1 true JO3370B1 (ar) 2019-03-13

Family

ID=47179020

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0332A JO3370B1 (ar) 2011-11-10 2012-11-04 طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Country Status (20)

Country Link
US (3) US20130122003A1 (ar)
EP (1) EP2776468B1 (ar)
JP (3) JP6144689B2 (ar)
KR (1) KR101718748B1 (ar)
CN (1) CN103930443B (ar)
AR (1) AR088671A1 (ar)
AU (2) AU2012335596B2 (ar)
BR (1) BR112014011211A2 (ar)
CA (1) CA2853836C (ar)
IL (2) IL231854A (ar)
IN (1) IN2014CN02923A (ar)
JO (1) JO3370B1 (ar)
MX (1) MX357837B (ar)
MY (1) MY163953A (ar)
RU (1) RU2648150C2 (ar)
SG (1) SG11201401286QA (ar)
TW (3) TW201806620A (ar)
UY (1) UY34444A (ar)
WO (1) WO2013071016A2 (ar)
ZA (1) ZA201402414B (ar)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2015200905A2 (en) * 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
US20180169230A1 (en) * 2015-05-29 2018-06-21 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
BR112018013407A2 (en) 2015-12-30 2018-12-18 Kodiak Sciences Inc. antibodies and conjugates thereof
CA3046489A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
SG11202008242XA (en) 2018-03-02 2020-09-29 Kodiak Sciences Inc Il-6 antibodies and fusion constructs and conjugates thereof
EP3765154A4 (en) 2018-03-14 2021-11-24 Celledit LLC MODIFICATION OF IMMUNE CELLS TO REDUCE TOXICITY AND USES THEREOF IN ADOPTIVE CELL THERAPY
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US20220096548A1 (en) * 2019-01-07 2022-03-31 Hunan Siweikang Therapeutics Co. Ltd. Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
KR20230150858A (ko) * 2021-02-27 2023-10-31 엘루미넥스 바이오사이언시스 (쑤저우) 리미티드 Il-6 수용체 및 혈관신생 인자를 표적화하는 항체 융합 단백질

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
JP4079461B2 (ja) 1994-12-29 2008-04-23 中外製薬株式会社 Ｉｌ−６アンタゴニストを含んでなる抗腫瘍剤の作用増強剤
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
RS50073B (sr) * 1999-06-08 2009-01-22 Regeneron Pharmaceuticals I.N.C., Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
AU2000279624A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR101420344B1 (ko) * 2003-07-02 2014-07-16 위니베르시따 디 제노바 Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법
US20070134242A1 (en) 2003-10-17 2007-06-14 Chugai Seiyaku Kabushiki Kaisha Mesothelioma therapeutic agent
AR057941A1 (es) 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
US20100322939A1 (en) * 2007-06-21 2010-12-23 Genmab A/S Novel methods for treating egfr-associated tumors
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN102292106B (zh) * 2008-11-25 2016-02-03 奥尔德生物制药公司 Il-6抗体及其用途
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Also Published As

Publication number Publication date
IL231854A0 (en) 2014-05-28
IL231854A (en) 2016-11-30
KR101718748B1 (ko) 2017-03-22
AU2018203666A1 (en) 2018-06-14
CA2853836C (en) 2019-07-23
BR112014011211A2 (pt) 2017-04-25
EP2776468B1 (en) 2018-01-24
MX2014004886A (es) 2014-07-09
RU2648150C2 (ru) 2018-03-22
ZA201402414B (en) 2015-03-25
WO2013071016A2 (en) 2013-05-16
KR20140095481A (ko) 2014-08-01
US20140322215A1 (en) 2014-10-30
US9409990B2 (en) 2016-08-09
IN2014CN02923A (ar) 2015-07-03
AR088671A1 (es) 2014-06-25
WO2013071016A3 (en) 2013-07-25
CN103930443A (zh) 2014-07-16
JP2017095489A (ja) 2017-06-01
US20130122003A1 (en) 2013-05-16
SG11201401286QA (en) 2014-05-29
MY163953A (en) 2017-11-15
AU2012335596B2 (en) 2018-05-17
US20170022279A1 (en) 2017-01-26
AU2012335596A1 (en) 2014-05-22
JP2018083841A (ja) 2018-05-31
TW201806620A (zh) 2018-03-01
CA2853836A1 (en) 2013-05-16
TW201332569A (zh) 2013-08-16
IL248620A0 (en) 2016-12-29
EP2776468A2 (en) 2014-09-17
CN103930443B (zh) 2017-08-04
JP2014534237A (ja) 2014-12-18
TW201716776A (zh) 2017-05-16
JP6283754B2 (ja) 2018-02-21
RU2014118739A (ru) 2015-12-20
UY34444A (es) 2013-05-31
JP6144689B2 (ja) 2017-06-07
MX357837B (es) 2018-07-26
TWI604852B (zh) 2017-11-11

Similar Documents

Publication Publication Date Title
JO3370B1 (ar) طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
EP4324479A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
MX368068B (es) Antagonista de il-4r para usarse para tratar la poliposis nasal.
EP4344706A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
MX363193B (es) Metodos para tratar la dermatitis atopica mediante la administracion de un antagonista de il-4r.
MX380220B (es) Composiciones farmacéuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofílica.
MX384192B (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
EA201301025A1 (ru) Преодоление устойчивости к ингибиторам пути erbb
EA201490369A1 (ru) Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
IN2014DN09098A (ar)
PH12012502022B1 (en) Anti-erbb3 antibodies
UA107827C2 (xx) Антитіло до cd40
EP4219552A3 (en) Il-11r binding proteins and uses thereof
SG10201807042YA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
WO2012071561A3 (en) Anti-il-6 antibodies for the treatment of anemia
MX339239B (es) Anticuerpos anti-cd40 y metodos de uso.
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
WO2016066634A3 (en) Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer
AU2014306956B2 (en) Methods for reducing exacerbation rates of asthma using benralizumab
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
MX360774B (es) Antagonistas de progesterona.
MX2015005928A (es) Metodos para tratar el cancer de ovario con antagonistas de dll4.
BR112014014824A2 (pt) anticorpos antagonistas do receptor do hormônio de crescimento humano e métodos de uso dos mesmos